Ron Lanton Ron Lanton

AI Is Accelerating Drug Development. Are the Commercial Agreements Keeping Up?

AI is changing pharmaceutical research and drug development, bringing new questions about intellectual property, licensing, milestone payments, and commercialization. As pharmaceutical companies partner with AI developers, their agreements must address who owns discoveries, how financial returns are divided, and what happens when compounds advance into clinical trials.

Read More
Ron Lanton Ron Lanton

Before a Health System Deploys Agentic AI

Agentic AI can do more than generate information. It can take action inside healthcare workflows. This article looks at the legal and operational issues health systems should consider before deployment, including authority, human oversight, patient data, cybersecurity, vendor contracts, auditability, and responsibility after implementation.

Read More